This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—Cytomegalovirus (CMV) infection of the retina is a well-recognized complication of immunosuppression or immunodeficiency. Recently, a new investigational agent for the treatment of CMV infection, 9-(1,3-dihydroxy-2-propoxymethyl)guanine (BW B759U, Burroughs Wellcome Co, Research Triangle Park, NC), has become available.1 We report CMV retinitis in a patient undergoing bone marrow transplantation, the response to therapy with BW B759U, and the subretinal fluid levels of that drug at the time of retinal reattachment surgery.
Report of a Case.
—A 13-year-old male bone marrow transplant patient was seen at the Wilmer Ophthalmological Institute,Baltimore, for retinitis. The patient was well until October 1983, when he was diagnosed as having acute myelogenous leukemia. His leukemia went into remission with chemotherapy, and in January 1984, he underwent an allogeneic bone marrow transplant. The patient never developed either acute or chronic graft-vs-host disease. In June 1984, he was found to have Candida esophagitis,
Jabs DA, Wingard JR, de Bustros S, de Miranda P, Saral R, Santos GW. BW B759U for Cytomegalovirus Retinitis: Intraocular Drug Penetration. Arch Ophthalmol. 1986;104(10):1436-1437. doi:10.1001/archopht.1986.01050220030009